10-Q: Xtant Medical Holdings Reports Q1 2025 Results, Revenue Up 18% Driven by Orthobiologics and Licensing

Xtant Medical Holdings, Inc. announces an 18% increase in revenue for the first quarter of 2025, driven by growth in orthobiologics sales and new licensing revenue.

Summary

• Xtant Medical Holdings, Inc. reported an 18% increase in total revenue for the three months ended March 31, 2025, reaching $32.9 million compared to $27.9 million in the same period last year.
• The increase was primarily driven by additional orthobiologics sales and $3.6 million in licensing revenue.
• The company's gross profit margin decreased slightly to 61.5% from 62.1% in the prior year, impacted by inventory write-offs and sales mix, partially offset by reduced product costs and greater scale.
• Operating expenses decreased by 7.7% to $19.18 million.
• The company reported net income of $58,000, a significant improvement from the net loss of $4.4 million in the first quarter of 2024.
• As of March 31, 2025, Xtant had $5.4 million in cash and cash equivalents and $5.7 million available under its revolving credit facility.
• On April 15, 2025, OrbiMed sold approximately 73.1 million shares of Xtant's common stock, resulting in Nantahala Capital Management holding 49.1% of the company's outstanding shares.
• The company amended its credit agreements to increase the common stock ownership threshold that triggers a change in control from 40% to 49.9%.

Sentiment

Score: 7

Explanation: The report shows positive revenue growth and a return to profitability, but there are concerns about gross margin decline and internal control weaknesses. The change in major shareholders could also introduce uncertainty.

Positives

• The company achieved an 18% increase in total revenue, indicating strong sales performance.
• The introduction of licensing revenue streams has positively impacted the company's financial results.
• The company turned a net loss into a net income, demonstrating improved profitability.
• The company is in compliance with all covenants under the credit agreements.
• The appointment of Mark A. Schallenberger as Chief Operating Officer could bring valuable leadership and operational expertise.

Negatives

• The gross profit margin experienced a slight decrease, primarily due to inventory write-offs and sales mix.
• The company's disclosure controls and procedures were not effective as of March 31, 2025, due to a material weakness in internal control over financial reporting.
• The company relies on independent sales agents and distributors, which could pose risks if these relationships are disrupted.

Risks

• The company's ability to increase revenue and improve gross margins is subject to various factors, including market conditions and competition.
• The company's ability to maintain sufficient liquidity and obtain financing on reasonable terms is crucial for funding operations.
• The company's dependence on independent sales agents and distributors could impact its ability to achieve expected results.
• Changes in reimbursement policies by CMS could affect the revenue recognized from license agreements.
• The company's internal control over financial reporting has a material weakness, which could affect the reliability of financial reporting.

Future Outlook

The company believes that its cash and cash equivalents, anticipated operating cash flows, and available credit will be sufficient to meet its anticipated cash requirements through at least May 2026, but may require or seek additional capital prior to that time.

Industry Context

The company operates in the regenerative medicine and medical device industry, focusing on orthobiologics and spinal implants. The market is competitive, with companies like Medtronic, Stryker, and Johnson & Johnson also offering products in this space. Xtant is focused on key growth initiatives including new product introductions, expanding its distribution network, penetrating adjacent markets, and leveraging its growth platform with technology and strategic acquisitions.

Comparison to Industry Standards

• Comparing Xtant's Q1 2025 revenue growth of 18% to larger players like Medtronic (which often reports single-digit growth) suggests Xtant is capturing market share or benefiting from specific product successes.
• However, Xtant's smaller scale means its results can be more volatile and influenced by individual deals, such as the licensing agreement that contributed significantly to Q1 revenue.
• Gross margin of 61.5% is within the typical range for medical device companies, but there is room for improvement to reach the higher end of the industry standard, as seen in companies with more established product lines and efficient manufacturing processes.
• Companies like NuVasive and Globus Medical, which focus on spinal implants, could be considered peers in terms of product focus, although they are significantly larger in terms of revenue and market capitalization.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the increased revenue and return to profitability.
• Employees may benefit from the company's growth and improved financial performance.
• Customers should see continued product availability and innovation.
• Suppliers may experience increased demand due to the company's growth.

Next Steps

• The company plans to continue focusing on its four key growth initiatives: introducing new products, expanding its distribution network, penetrating adjacent markets, and leveraging its growth platform with technology and strategic acquisitions.
• The company intends to prepare and file a shelf resale registration statement with the SEC within 30 days of April 15, 2025, for purposes of registering the resale of the shares of common stock purchased by Nantahala and other purchasers.

Key Dates

Keywords

revenue, orthobiologics, licensing, spinal implants, financial results, Q1 2025, Xtant Medical, net income, gross margin